Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q3 EPS of ($0.66), $0.06 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $9 million versus the consensus estimate of $10.87 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.